Digital Health Valuation Multiples
Explore private market Digital Health valuation multiples with benchmarks structured by stage and region. Updated quarterly.
Digital Health
Digital Health companies develop software, platforms, and connected devices that improve healthcare delivery, patient outcomes, and clinical workflows. Private market valuations reflect regulatory pathway clarity, clinical evidence, health system adoption rates, and the ability to demonstrate measurable improvements in care quality or cost efficiency.
The category spans telehealth platforms, remote patient monitoring, clinical decision support, electronic health records, and wellness applications. DealMatrix tracks valuation dynamics across 7 funding stages and all major global regions, updated every quarter.
Sector
Digital Health
Health & Life Sciences
Sector tracked since
2000
25+ years of data
EV/SALES & EV/EBITDA ACROSS
6 Regions · 7 Stages
Modelled independently via proprietary econometric approach
UPDATE FREQUENCY
Quarterly
Data updates & model improvement
Digital Health Valuation Multiples
Sector benchmark as of 31 March 2025 · median across 6 regions · updated quarterly
How we derive these multiples
DealMatrix multiples are derived from institutional-grade public-market index data covering ~150 GICS sub-industries across 6 regions, with quarterly history back to 2000. Regional scaling follows Damodaran (NYU Stern), and the methodology follows the IPEV Guidelines 2025. Published benchmarks are illustrative and dated; because IPEV 2025 prohibits static multiples for reporting periods from 1 April 2026, current quarterly data for valuation work is available on the platform.
The Venionaire DealMatrix Multiples Model
DealMatrix multiples are proprietary private-market benchmarks, derived through a six-step model that translates public capital-market index comparables into private-market segments and funding stages, adjusted for macroeconomic conditions.
The model produces three components: The reported public multiple, the model-predicted multiple, and the lower bound predicted multiple averaged into the DealMatrix Composite, then adjusted for region and funding stage. The methodology follows the IPEV Guidelines 2025.
Pet Love Boom Fuels Lassie’s $75m Series C as It Moves to Own the Future of Pet Care in Europe
raised
Valuation
VisionHealth Raises EUR 1.5M in Funding
raised
Valuation
Eden Health Raises USD 60M in Series C Funding
raised
Valuation
Telemedico gets USD 6.6M to grow the reach of its digital health SaaS
raised
Valuation
Six-digit follow-up investment for health startup myBioma
raised
Valuation
Health & Life Sciences
Pharmaceutical
Health & Life Sciences
MedTech
Health & Life Sciences
BioTech
Digital Health Valuation Multiples — FAQ
What is the average valuation multiple for Digital Health companies?
As of 31 March 2025, the Digital Health sector benchmark was an EV/Sales multiple of about 4.4× and an EV/EBITDA multiple of about 23.2× (median across six regions). Multiples vary by funding stage and region; stage-level and current-quarter figures are available in DealMatrix.
What is the difference between EV/Sales and EV/EBITDA for Digital Health?
EV/Sales (enterprise value ÷ revenue) is used for high-growth Digital Health companies that are not yet profitable, while EV/EBITDA (enterprise value ÷ operating profit) applies to mature, profitable ones. Early-stage companies are usually benchmarked on EV/Sales.
How are Digital Health valuation multiples calculated?
Each Digital Health multiple is a weighted blend of public-market index comparables, cleaned for outliers and gaps, then adjusted for macroeconomic conditions, region, and funding stage through a six-step model that follows the IPEV Guidelines 2025.
Do Digital Health valuation multiples vary by region?
Yes. North America serves as the reference market and typically carries the highest multiples, while emerging markets trade at a structural discount. Region-specific figures are available in the DealMatrix platform.
How current is this Digital Health data and how often is it updated?
The benchmark shown is an illustrative annual figure as of 31 March 2025. The underlying model is updated every quarter. Because the IPEV Guidelines 2025 prohibit static multiples for reporting periods from 1 April 2026, current quarterly data for valuations is available in the DealMatrix platform.